Fig. 2From: Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editingObtaining hiPS cells from different cell sources in order to use them as a disease model, drug developmental model, or stem cell research. hiPS cells from a PID patient may be corrected with the goal of developing a cell-based therapy. Adapted from [37]Back to article page